Sonja Zweegman

32.6k total citations · 3 hit papers
334 papers, 10.4k citations indexed

About

Sonja Zweegman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sonja Zweegman has authored 334 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 250 papers in Hematology, 147 papers in Oncology and 132 papers in Molecular Biology. Recurrent topics in Sonja Zweegman's work include Multiple Myeloma Research and Treatments (189 papers), Protein Degradation and Inhibitors (62 papers) and Peptidase Inhibition and Analysis (45 papers). Sonja Zweegman is often cited by papers focused on Multiple Myeloma Research and Treatments (189 papers), Protein Degradation and Inhibitors (62 papers) and Peptidase Inhibition and Analysis (45 papers). Sonja Zweegman collaborates with scholars based in Netherlands, United States and Italy. Sonja Zweegman's co-authors include Niels W.C.J. van de Donk, Pieter Sonneveld, Henk M. Lokhorst, Tuna Mutis, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis, Evangelos Terpos, Jacqueline Cloos, Meletios Α. Dimopoulos and Philippe Moreau and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Sonja Zweegman

313 papers receiving 10.3k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Jesús F. San Miguel et al. profile →
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
T-cell-engaging bispecific antibodies in cancer

2023 139 citations Niels W.C.J. van de Donk, Sonja Zweegman profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sonja Zweegman Netherlands	55	6.5k	5.1k	4.6k	1.5k	1.5k	334	10.4k
Seema Singhal United States	50	7.0k 1.1×	4.6k 0.9×	4.0k 0.9×	1.3k 0.9×	1.1k 0.7×	291	10.7k
Michèle Cavo Italy	62	11.3k 1.8×	7.7k 1.5×	6.7k 1.4×	2.2k 1.5×	1.3k 0.9×	557	14.5k
David S. Siegel United States	59	11.3k 1.7×	10.1k 2.0×	7.6k 1.6×	1.6k 1.1×	1.2k 0.8×	415	15.8k
Roland B. Walter United States	53	6.7k 1.0×	3.7k 0.7×	3.2k 0.7×	1.4k 0.9×	1.6k 1.1×	365	11.0k
Joan Bladé Spain	61	12.1k 1.9×	9.3k 1.8×	6.9k 1.5×	2.4k 1.6×	1.0k 0.7×	324	14.8k
Parameswaran Hari United States	43	4.4k 0.7×	3.6k 0.7×	3.8k 0.8×	945 0.6×	1.2k 0.8×	420	7.8k
James R. Berenson United States	58	6.7k 1.0×	5.9k 1.1×	7.9k 1.7×	856 0.6×	1.7k 1.2×	389	14.0k
Jane L. Liesveld United States	47	3.7k 0.6×	2.8k 0.5×	2.3k 0.5×	1.4k 0.9×	1.6k 1.1×	252	8.3k
Mario Boccadoro Italy	60	10.9k 1.7×	8.3k 1.6×	7.4k 1.6×	2.2k 1.4×	2.5k 1.7×	479	15.9k
Hartmut Goldschmidt Germany	68	12.5k 1.9×	10.1k 2.0×	8.0k 1.7×	2.2k 1.5×	1.9k 1.3×	660	18.4k

Countries citing papers authored by Sonja Zweegman

Since Specialization

Citations

This map shows the geographic impact of Sonja Zweegman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonja Zweegman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonja Zweegman more than expected).

Fields of papers citing papers by Sonja Zweegman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonja Zweegman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonja Zweegman. The network helps show where Sonja Zweegman may publish in the future.

Co-authorship network of co-authors of Sonja Zweegman

This figure shows the co-authorship network connecting the top 25 collaborators of Sonja Zweegman. A scholar is included among the top collaborators of Sonja Zweegman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonja Zweegman. Sonja Zweegman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Jiaxian, Ricardo De Matos Simoes, Ruud Ruiter, et al.. (2025). Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease. Biomolecules. 15(12). 1747–1747.

Verkleij, Christie P.M., et al.. (2024). Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing. HemaSphere. 8(7). e132–e132. 7 indexed citations

Voss, Marise R. Heerma van, Remco J. Molenaar, Imke H. Bartelink, et al.. (2024). T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement. Expert Opinion on Biological Therapy. 24(9). 889–901. 1 indexed citations

Donk, Niels W.C.J. van de & Sonja Zweegman. (2023). Monoclonal Antibodies in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America. 38(2). 337–360. 6 indexed citations

Katsarou, Afroditi, Renée Poels, Esther Drent, et al.. (2021). Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. Clinical Cancer Research. 27(13). 3793–3803. 47 indexed citations

Douma, Joeri A J, et al.. (2020). Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. Supportive Care in Cancer. 29(7). 3783–3792. 4 indexed citations

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations

Terpos, Evangelos, Monika Engelhardt, Gordon Cook, et al.. (2020). Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 34(8). 2000–2011. 81 indexed citations

Frerichs, Kristine A., Marloes E.C. Broekmans, Berris van Kessel, et al.. (2020). Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research. 26(9). 2203–2215. 68 indexed citations

10.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2019). Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 104(11). 2274–2282. 23 indexed citations

11.

Wester, Ruth, Bronno van der Holt, Sonja Zweegman, et al.. (2019). Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica. 104(11). 2265–2273. 22 indexed citations

12.

Drent, Esther, Renée Poels, Ruud Ruiter, et al.. (2019). Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells. Clinical Cancer Research. 25(13). 4014–4025. 135 indexed citations

13.

Caers, Jo, Bruno Paiva, Elena Zamagni, et al.. (2018). Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology & Oncology. 11(1). 10–10. 152 indexed citations

14.

Krejcik, Jakub, Inger S. Nijhof, Berris van Kessel, et al.. (2017). Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research. 23(24). 7498–7511. 119 indexed citations

15.

Cook, Gordon, Sonja Zweegman, María‐Victoria Mateos, Florence Suzan, & Philippe Moreau. (2017). A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology. 121. 74–89. 26 indexed citations

16.

Minnema, Monique C., Kazem Nasserinejad, Bouke P. C. Hazenberg, et al.. (2017). HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS. Data Archiving and Networked Services (DANS). 1 indexed citations

17.

Nijhof, Inger S., Tineke Casneuf, Berris van Kessel, et al.. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 128(7). 959–970. 275 indexed citations

18.

Donk, Niels W.C.J. van de, Antonio Palumbo, Hans Erik Johnsen, et al.. (2014). The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 99(6). 984–996. 107 indexed citations

19.

Regelink, Josien C., Monique C. Minnema, Evangelos Terpos, et al.. (2013). Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review. British Journal of Haematology. 162(1). 50–61. 142 indexed citations

20.

Netelenbos, Tanja, Sonja Zweegman, J W van Oostveen, et al.. (2003). Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia. 17(1). 175–184. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact